This episode of Winning IR explores the challenges faced by IROs and issuers in new and emerging industries. Leah Gibson, Vice President, Investor Relations & Strategic Communications at Cybin Inc., joins Mark Fasken to share her perspective from transitioning from a traditional biotech company to one developing treatments derived from psilocybin, a Schedule 1 Substance in the US.

Listen to the episode or read the transcript to learn more about:

• The similarities and differences between  IR for traditional and emerging companies.
• How to address gaps in investor education.
• Managing the risks and challenges associated with early stage companies. 
• How to manage communication with diverse audiences, including retail investors.
• Strategies for staying abreast of changes in a dynamic industry. 
• How to successfully engage with an audience of retail investors.
• How does being in a tightly regulated industry affect your IR strategy? 
• What is the most important thing for an IRO representing an emerging industry to know?

About our Guest:

Leah Gibson is a life sciences investor relations leader with nearly two decades of experience in corporate and shareholder communications, and business strategy development. She has worked with small-, mid- and large-cap publicly traded biotechnology companies in North America, including a $60B large-cap U.S. biotech focused on creating transformative medicines for serious genetic diseases.

Connect with Leah on LinkedIn here.

Winning IR is brought to you by Irwin.

For more winning ideas, subscribe to Winning IR wherever you get your podcasts.

For more information, visit getirwin.com/winning-ir